Sökning: onr:"swepub:oai:DiVA.org:kth-316306" >
Challenges of rapam...
Challenges of rapamycin repurposing as a potential therapeutic candidate for COVID-19 : implications for skeletal muscle metabolic health in older persons
-
- Lees, Matthew J. (författare)
- Univ Toronto, Fac Kinesiol & Phys Educ, Dept Exercise Sci, Toronto, ON, Canada.
-
- Hodson, Nathan (författare)
- Manchester Metropolitan Univ, Musculoskeletal Sci & Sports Med Res Ctr, Dept Sport & Exercise Sci, Manchester, Lancs, England.
-
- Tinline-Goodfellow, Cassidy T. (författare)
- Univ Toronto, Fac Kinesiol & Phys Educ, Dept Exercise Sci, Toronto, ON, Canada.
-
visa fler...
-
- Fung, Hugo J. W. (författare)
- Univ Toronto, Fac Kinesiol & Phys Educ, Dept Exercise Sci, Toronto, ON, Canada.
-
- Elia, Antonis, Dr (författare)
- KTH,Omgivningsfysiologi
-
- Moore, Daniel R. (författare)
- Univ Toronto, Fac Kinesiol & Phys Educ, Dept Exercise Sci, Toronto, ON, Canada.
-
visa färre...
-
Univ Toronto, Fac Kinesiol & Phys Educ, Dept Exercise Sci, Toronto, ON, Canada Manchester Metropolitan Univ, Musculoskeletal Sci & Sports Med Res Ctr, Dept Sport & Exercise Sci, Manchester, Lancs, England. (creator_code:org_t)
- American Physiological Society, 2022
- 2022
- Engelska.
-
Ingår i: American Journal of Physiology. Endocrinology and Metabolism. - : American Physiological Society. - 0193-1849 .- 1522-1555. ; 322:6, s. E551-E555
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged as the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic that has spread worldwide, resulting in over 6 million deaths as of March 2022. Older people have been disproportionately affected by the disease, as they have a greater risk of hospitalization, are more vulnerable to severe infection, and have higher mortality than younger patients. Although effective vaccines have been rapidly developed and administered globally, several clinical trials are ongoing to repurpose existing drugs to combat severe infection. One such drug, rapamycin, is currently under study for this purpose, given its immunosuppressant effects that are mediated by its inhibition of the mechanistic target of rapamycin (mTOR), a master regulator of cell growth. Consistent with this premise, acute rapamycin administration in young healthy humans blocks or attenuates mTOR and its downstream effectors, leading to the inhibition of muscle protein synthesis (MPS). Skeletal muscle mass declines when MPS is chronically lower than muscle protein breakdown. This is consequential for older people who are more susceptible to anabolic resistance (i.e., the blunting of MPS) due to reduced activity, sedentariness, or bed rest such as that associated with COVID-19 hospitalization, and who have also demonstrated a delayed or blunted ability to regain inactivity-induced muscle loss. The lack of studies investigating rapamycin administration on skeletal muscle in older people, and the emergence of effective antiviral medications against severe infection, may indicate the reduced relevance of drug repurposing for present or future pandemics.
Nyckelord
- aging
- anabolic resistance
- mTOR
- muscle protein synthesis
- SARS-CoV-2
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas